Bookmark and Share

Matthew B Laurens
 

Matthew B Laurens M.D., M.P.H.

Academic Title: Associate Professor
Primary Appointment: Pediatrics
Secondary Appointments: Medicine
mlaurens@medicine.umaryland.edu
Location: HSF-I, 480
Phone: 410-706-5462
Fax: 410-706-1204

Personal History:

  • 1992: B.S. Biology, Oglethorpe University, Atlanta Georgia 
  • 1992-1994: Guinea Worm eradication, U.S. Peace Corps, Benin, West Africa 
  • 1994-1995: Project supervisor for hygiene behavior studies, UNICEF, Benin, West Africa 
  • 1996-1997: Instructor in Biostatistics and Epidemiology, Mercer University School of Medicine 
  • 2001: Doctor of Medicine, Mercer Unviersity School of Medicine, Macon, Georgia 
  • 2001-2004: Residency in Pediatrics, Tulane University School of Medicine 
  • 2004-2005: Chief Residency in Pediatrics, Tulane Unviersity School of Medicine 
  • 2005-2008: Fellowship in Pediatric Infectious Diseases and Tropical Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland
  • 2008-2009: Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases

Research Interests:

Dr. Laurens is a pediatric infectious disease specialist, with a primary research interest in malaria and antimalarial immunity. He conducts studies in Baltimore at the CVD and at international sites in Mali and Malawi to evaluate malaria vaccines and therapeutics, to study the interaction of HIV and malaria, and to investigate the acquisition of antimalarial immunity. The broad goal of Dr. Laurens’ research is to illuminate the mechanisms of immunity to malaria with the aim to inform development of malaria vaccines and therapeutics.

Clinical Speciality:

  • Pediatrics
  • Pediatric Infectious Diseases

Publications:

  1. Laurens MB, Becker RM, Johnson JK, Wolf JS, Kotloff KL. MRSA with progression from otitis media and sphenoid sinusitis to clival osteomyelitis, pachymeningitis and abducens nerve palsy in an immunocompetent 10 year-old patient. International Journal of Pediatric Otorhinolaryngology. 2008 Jul;72(7): 945-51.
  2. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens MB, Plowe CV, Sim BKL. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparummalaria. Human Vaccines. 2010 Jan 21;6: 97-106.
  3. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois M, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV. Safety and Immunogenicity of an AMA1 Malaria Vaccine in Malian Children: Results of a Phase 1 Randomized Controlled Trial. PLoS One. 2010 Feb 04;5(2):e9041.
  4. Lyke KE, Laurens MB, Adams M, Billingsley PF, Richman A, Loyevsky M, Chakravarty S, Plowe CV, Sim KL, Edelman R, Hoffman SL. Plasmodium falciparum Malaria Challenge by the Bite of Aseptic Anopheles stephensi Mosquitoes: Results of a Randomized Infectivity Trial. PLoS One. 2010 Oct 21;5(10):e13490.
  5. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV. A field trial to assess a blood stage malaria vaccine. New England Journal of Medicine. 2011 Sep 14;365(11):1004-13.
  6. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL. Live Attenuated Malaria Vaccine Designed to Protect through Hepatic CD8+ T Cell Immunity. Science. 2011Oct 28;334(6055): 475-480.
  7. Laurens MB*, Duncan CJ, Epstein JE, Hill AV, Komisar JL, Lyke KE, Ockenhouse CF, Richie TL, Roestenberg M, Sauerwein RW, Spring MD, Talley AK, Moorthy VS; The Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection. A consultation on the optimization of controlled human malaria infection by mosquito bite for the evaluation of candidate malaria vaccines. Vaccine. 2012 Aug 3;30(36):5302-5304.
  8. Shakuat AM, Gilliams EA, Kenefic LJ, Laurens MB, Dzinjalamala FK, Nyirenda OM, Thesing PC, Jacob CG, Molyneux ME, Taylor TE, Plowe CV, Laufer MK. Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment. Malaria Journal. 2012 Jun 18;11(1): 207.
  9. Laufer MK, Thesing PC, Dzinjalamala FK, Nyirenda OM, Masonga R, Laurens MB, Stokes-Riner A, Taylor TE, and Plowe CV. A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin, or atovaquone-proguanil to treat malaria. PLoS One. 2012 Aug 17;7(8):e42284.
  10. Boyd MA, Laurens MB, Fiorella PD, Mendley SR. Peritonitis and technique failure caused by Roseomonas mucosa in an adolescent with HIV on continuous cycling peritoneal dialysis. Journal of Clinical Microbiology. 2012 Nov;50(11):3801-4.
  11. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J, Blackwelder WC, Dube T, Laurens MB, Doumbo OK, and Plowe CV. Molecular Basis of Allele-Specific Efficacy of a Blood-Stage Malaria Vaccine: Vaccine Development Implications. The Journal of Infectious Diseases. 2013 Feb 1;207(3):511-9.
  12. Coulibaly D, Rebaudet S, Travassos M, Tolo Y, Laurens M, Kone AK, Traore K, Guindo A, Diarra I, Niangaly A, Daou M, Dembele A, Sissoko M, Kouriba B, Dessay N, Gaudart J, Piarroux R, Thera MA, Plowe CV, Doumbo OK. Spatio-temporal analysis of malaria within a transmission season in Bandiagara, Mali. Malaria Journal. 2013 Mar 1;12(1):82.
  13. Travassos MA, Niangaly A, Bailey JA, Ouattara A, Coulibaly D, Laurens MB, Pablo J, Jasinskas A, Nakajima-Sasaki R, Berry AA, Takala-Harrison S, Kouriba B, Rowe JA, Lyke KE, Doumbo OK, Thera MA, Felgner PL, Plowe CV. Seroreactivity to Plasmodium falciparum Erythrocyte Membrane Protein 1 Intracellular Domain in Malaria-Exposed Children and Adults. J Infect Dis. 2013 Aug 14;PubMed PMID: 23901079.
  14. Seder RA, Chang LJ, Enama ME, Zephir KL, Sarwar UN, Gordon IJ, Holman LA, James ER, Billingsley PF, Gunasekera A, Richman A, Chakravarty S, Manoj A, Velmurugan S, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Plummer SH, Hendel CS, Novik L, Costner PJ, Mendoza FH, Saunders JG, Nason MC, Richardson JH, Murphy J, Davidson SA, Richie TL, Sedegah M, Sutamihardja A, Fahle GA, Lyke KE, Laurens MB, Roederer M, Tewari K, Epstein JE, Sim BK, Ledgerwood JE, Graham BS, Hoffman SL, the VRC 312 Study Team. Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. Science. 2013 Aug 8;PubMed PMID: 23929949.
  15. Laurens MB, Billingsley P, Richman A, Eappen AG, Adams M, Li T, Chakravarty S, Gunasekera A, Jacob CG, Sim BK, Edelman R, Plowe CV, Hoffman SL, Lyke KE. Successful Human Infection with P falciparum Using Three Aseptic Anopheles stephensi Mosquitoes: A New Model for Controlled Human Malaria Infection. PLoS One. 2013;8(7):e68969. PubMed PMID: 23874828; PubMed Central PMCID: PMC3712927.
  16. Laurens MB, Thera MA, Coulibaly D, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Dube T, Soisson L, Diggs CL, House B, Bennett JW, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV, Doumbo OK. Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in Malian children: 24-month follow-up of a randomized, double-blinded phase 2 trial. PLoS One. 2013 Nov 18;8(11):e79323.
  17. Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW. External quality assurance of malaria nucleic Acid testing for clinical trials and eradication surveillance. PLoS One. 2014 May 16;9(5):e97398.